Arrowhead Pharmaceuticals (ARWR) Projected to Post Quarterly Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) will likely be issuing its Q1 2026 results after the market closes on Thursday, February 5th. Analysts expect Arrowhead Pharmaceuticals to post earnings of $0.82 per share and revenue of $225.6580 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals Trading Down 1.2%

Shares of ARWR opened at $72.14 on Wednesday. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76. The stock has a market cap of $10.10 billion, a PE ratio of -901.64 and a beta of 1.21. The firm’s fifty day moving average is $66.29 and its two-hundred day moving average is $42.76. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 130,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the completion of the transaction, the chief executive officer owned 3,971,255 shares of the company’s stock, valued at $273,420,906.75. This trade represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael S. Perry sold 16,250 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the sale, the director owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This represents a 12.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 510,836 shares of company stock worth $33,603,060. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. iSAM Funds UK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $29,000. Quadrant Capital Group LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth $140,000. Daiwa Securities Group Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 3,763 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth $91,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at $224,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Chardan Capital upped their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Bank of America upped their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, January 21st. The Goldman Sachs Group upped their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Finally, Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.67.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.